Global Lung Cancer Therapeutics Market Segmentation, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma, Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) – Industry Trends and Forecast to 2031
Lung Cancer Therapeutics Market Analysis
Cancer refers to a disease of genes that are caused due to abnormal growth of cells. Through blood and lymph system these abnormal cells further migrate from the original site to other site. Lung cancer is type of cancer that is formed in tissues of the lungs. The rise in awareness regarding cancer is escalating the growth of lung cancer therapeutics market.
Lung Cancer Therapeutics Market Size
Global lung cancer therapeutics market size was valued at USD 30.06 billion in 2023 and is projected to reach USD 66.33 billion by 2031, with a CAGR of 10.41% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes
|
Lung Cancer Therapeutics Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Key Market Players
|
Church & Dwight Co., Inc. (US), GlaxoSmithKline plc. (UK), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), ONO PHARMACEUTICAL CO., LTD. (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Lily. (US), AstraZeneca (US), Boehringer Ingelheim International GmbH (Germany), Merck & Co., Inc. (US), CELGENE CORPORATION (US), Sanofi (France), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), ALLERGAN (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), and Bristol-Myers Squibb Company (US), among others
|
Lung Cancer Therapeutics Market Definition
Lung Cancer therapeutic refer to the therapies that include drugs and surgery aimed to stunt, kill, diminish or destroy the cancerous growth and cells in the lungs. This type of cancer is treated through chemotherapy, immunotherapy, surgery, and radiation therapy. The primary lung carcinomas usually originate from the epithelial cells.
Lung Cancer Therapeutics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Prevalence of Unhealthy Lifestyles
The rise in the adoption of the unhealthy lifestyles, such as smoking acts as one of the major factors driving the growth of lung cancer therapeutics market. Cigarette smoking is known to be prominent cause of lung cancer.
- Demand for Targeted Therapies
The increase in the demand for targeted therapies, including chemotherapy, immunotherapy, surgery, and radiation therapy to treat lung cancer accelerate the market growth.
- Presence of Highly Efficient Drugs
The presence of highly efficient drugs, such as avastin, gemzar, taxotere and tarceva further influence the market.
Opportunities
Furthermore, arrival of nanomedicine to treat lung cancer extend profitable opportunities to the market players in the forecast period of 2024 to 2031. Also, growing approvals in the lung cancer therapeutics will further expand the market.
Restraints/Challenges
On the other hand, presence of poor cancer diagnostic facilities in many countries and the adverse effects of chemotherapies are expected to obstruct market growth. Also, stringent regulations are projected to challenge the lung cancer therapeutics market in the forecast period of 2024-2031.
This lung cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lung Cancer Therapeutics Market Scope
The biomarkers market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Non-Small Cell Lung Cancer
- Metastatic Lung Cancer
- Mesothelioma
- Chest Wall Tumours
- Pulmonary Neuroendocrine Tumours
- Mediastinal Tumours
Molecule Type
- Small Molecules
- Biologics
Drug Class
- Alkylating Agents
- Antimetabolites
- Mitotic Inhibitors
- Multikinase Inhibitors
- EGFR Inhibitors
- Others
Treatment Type
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Other Drugs
Therapy Type
- Single Drug Therapy
- Combination Therapy
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online
- Others
Lung Cancer Therapeutics Market Regional Analysis
The lung cancer therapeutics market is analyzed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.
The countries covered in the lung cancer therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lung cancer therapeutics market because of the rise in incidence of lung cancer and growing aging population within the region.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increased use of lung cancer therapeutic due to rising tobacco smoking in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Lung Cancer Therapeutics Market Share
The lung cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer therapeutics market.
Lung Cancer Therapeutics Market Leaders Operating in the Market Are:
- Church & Dwight Co., Inc. (US)
- GlaxoSmithKline plc. (UK)
- Pfizer Inc. (US)
- Sun Pharmaceutical Industries Ltd. (India)
- Takeda Pharmaceutical Company Limited (Japan)
- ONO PHARMACEUTICAL CO., LTD. (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Lily. (US)
- AstraZeneca (US)
- Boehringer Ingelheim International GmbH (Germany)
- Merck & Co., Inc. (US)
- CELGENE CORPORATION (US)
- Sanofi (France)
- Johnson & Johnson Services, Inc. (US)
- Dr. Reddy’s Laboratories Ltd. (India)
- ALLERGAN (Ireland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol-Myers Squibb Company (US)
Latest Developments in Lung Cancer Therapeutics Market
- AdoRx Therapeutics, announced regarding their strategic collaboration with Lung Cancer Initiative at Johnson & Johnson and Johnson & Johnson Innovation LLC in February’2019. AdoRx has granted an exclusive option to research, develop and commercialise novel antagonists under the terms of the agreement
SKU-